Research Analysts Offer Predictions for LFCR Q4 Earnings

Lifecore Biomedical, Inc. (NASDAQ:LFCR) – Stock analysts at Barrington Research issued their Q4 2025 earnings estimates for Lifecore Biomedical in a research report issued to clients and investors on Monday, November 10th. Barrington Research analyst M. Petusky forecasts that the company will post earnings of ($0.15) per share for the quarter. The consensus estimate for Lifecore Biomedical’s current full-year earnings is ($0.91) per share. Barrington Research also issued estimates for Lifecore Biomedical’s Q1 2026 earnings at ($0.20) EPS, Q2 2026 earnings at ($0.18) EPS, Q3 2026 earnings at ($0.20) EPS, Q4 2026 earnings at ($0.17) EPS, FY2026 earnings at ($0.82) EPS, Q1 2027 earnings at ($0.20) EPS, Q2 2027 earnings at ($0.18) EPS, Q3 2027 earnings at ($0.20) EPS, FY2027 earnings at ($0.75) EPS and FY2028 earnings at ($0.77) EPS.

Lifecore Biomedical (NASDAQ:LFCR) last posted its quarterly earnings results on Monday, April 1st. The company reported ($0.22) EPS for the quarter. Lifecore Biomedical had a negative net margin of 31.70% and a negative return on equity of 846.51%. The firm had revenue of $26.54 million for the quarter. Lifecore Biomedical has set its FY 2024 guidance at EPS.

Several other equities research analysts have also recently commented on the company. KeyCorp initiated coverage on Lifecore Biomedical in a research report on Wednesday, September 3rd. They set a “sector weight” rating on the stock. Wall Street Zen upgraded shares of Lifecore Biomedical from a “sell” rating to a “hold” rating in a research note on Saturday, August 16th. Finally, Weiss Ratings restated a “sell (d)” rating on shares of Lifecore Biomedical in a report on Wednesday, October 8th. Two analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Lifecore Biomedical has an average rating of “Hold” and a consensus price target of $8.00.

Lifecore Biomedical Stock Performance

Shares of LFCR opened at $8.22 on Wednesday. The company has a market cap of $307.97 million, a price-to-earnings ratio of -6.27 and a beta of 0.61. The business’s fifty day simple moving average is $7.13 and its two-hundred day simple moving average is $7.23. Lifecore Biomedical has a 12 month low of $4.76 and a 12 month high of $8.85. The company has a current ratio of 2.84, a quick ratio of 1.77 and a debt-to-equity ratio of 113.76.

Institutional Investors Weigh In On Lifecore Biomedical

A number of hedge funds have recently modified their holdings of LFCR. Vanguard Group Inc. increased its stake in shares of Lifecore Biomedical by 0.8% in the 3rd quarter. Vanguard Group Inc. now owns 1,622,769 shares of the company’s stock worth $11,944,000 after purchasing an additional 12,851 shares in the last quarter. State of Wyoming bought a new position in shares of Lifecore Biomedical in the second quarter worth about $69,000. Tactive Advisors LLC purchased a new position in shares of Lifecore Biomedical during the 2nd quarter valued at about $126,000. Grizzlyrock Capital LLC bought a new position in shares of Lifecore Biomedical during the 2nd quarter valued at approximately $5,964,000. Finally, The Manufacturers Life Insurance Company purchased a new stake in Lifecore Biomedical in the 2nd quarter worth approximately $88,000. Institutional investors own 83.36% of the company’s stock.

About Lifecore Biomedical

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.